Bioelectrochemical systems and Engineering Research Group






Gox
MFClogo
acs1
FeNP










Electrochemical biosensor for Non-estified fatty acid (NEFA)

With an increase in people being diagnosed with type 2 diabetes (T2D), there is a high demand in biosensors that can monitor not only the blood glucose levels but also the other biomarkers associated with T2D. The metabolism biomarkers are essential in understanding the cause of diabetes at the early stage. Diets rich in saturated fats cause obesity and insulin resistance, and increase levels of circulating NEFAs. Assessment of NEFA may be a useful addition to routine diabetes management. NEFA, like glucose can reflect acute change of an individualís energy status. Glucose and NEFA are biomarkers of immediate energy metabolism.

The specific research interest of this project is to develop an electrochemical biosensor that will detect changes in blood NEFA concentrations for patients with T2D, for the future development of personalised intervention programmes for the treatment and management of the disease.

Biosensors detecting biomarkers for Dementia diagnosis

More than 30% of older people in the community have either a high risk of

developing dementia, or live unaware that they have it.  Diagnosis of dementia requires extensive clinical screening, supported by neuroradiological assessments, and needs to be done in highly specialised clinics. Currently, the dementia diagnosis rate is low. The diagnostic process is lengthy, and can delay the currently available anti-dementia treatments. Diagnostic tests able to detect dementia syndromes with high sensitivity and specificity in living subjects are urgently needed. In collaboration with Dr Elizabeta Mukaetova-Ladinska, a clinician who has many years clinical and research experience in relation to dementia, a panel of blood (platelet and plasma) biomarkers have been recently identified,  that promise clinical utility with respect to differentiating specific stages of dementia progression, and have a potential for clinical guiding and optimising therapy. Electrochemical based biosensors to detect these blood biomarkers are under development.




NEFA


a
Last updated in May 2013